Form D · Biotechnology
Drais Pharmaceuticals Inc
Bridgewater, NJ · CIK 0001422847
Offering snapshot reported Feb 22, 2010 · SEC filing
- Reported sold
- $20M Indefinite offering
- Investors reported
- 31 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Dec 14, 2007 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Feb 22, 2010 | Amendment | $20,000,000 | No comparison | 31 | SEC filing |
| Jan 2, 2008 | Paper | Not reported | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Not reported
- Exemptions
- 06
- Duration over one year
- Yes
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-112966
Source: Form D, filed Feb 22, 2010. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Jeff Bird | Director |
| Robert Desjardins | Director, Executive |
| Arnold Oronsky | Executive |
| Donna Tempel | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
520 Us Highway 22, Suite 201
Bridgewater, NJ, 08807
Bridgewater, NJ, 08807